Superiority of Rasburicase Versus Allopurinol on Serum Uric Acid Control in Adult Patients with Hematological Malignancies at Risk of Developing Tumor Lysis Syndrome: Results of a Randomized Comparative Phase III Study
Publication
, Conference
Cortes, J; Seiter, K; Maziarz, RT; Wetzler, M; Craig, M; Matous, J; Luger, S; Dey, B; Schiller, GJ; Pham, D; Abboud, CN; Krishnamurthy, M ...
Published in: BLOOD
November 16, 2008
Duke Scholars
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2008
Volume
112
Issue
11
Start / End Page
340 / 341
Location
San Francisco, CA
Publisher
AMER SOC HEMATOLOGY
Conference Name
50th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Cortes, J., Seiter, K., Maziarz, R. T., Wetzler, M., Craig, M., Matous, J., … Moore, J. O. (2008). Superiority of Rasburicase Versus Allopurinol on Serum Uric Acid Control in Adult Patients with Hematological Malignancies at Risk of Developing Tumor Lysis Syndrome: Results of a Randomized Comparative Phase III Study. In BLOOD (Vol. 112, pp. 340–341). San Francisco, CA: AMER SOC HEMATOLOGY.
Cortes, Jorge, Karen Seiter, Richard Thomas Maziarz, Meir Wetzler, Michael Craig, Jeffrey Matous, Selina Luger, et al. “Superiority of Rasburicase Versus Allopurinol on Serum Uric Acid Control in Adult Patients with Hematological Malignancies at Risk of Developing Tumor Lysis Syndrome: Results of a Randomized Comparative Phase III Study.” In BLOOD, 112:340–41. AMER SOC HEMATOLOGY, 2008.
Cortes J, Seiter K, Maziarz RT, Wetzler M, Craig M, Matous J, et al. Superiority of Rasburicase Versus Allopurinol on Serum Uric Acid Control in Adult Patients with Hematological Malignancies at Risk of Developing Tumor Lysis Syndrome: Results of a Randomized Comparative Phase III Study. In: BLOOD. AMER SOC HEMATOLOGY; 2008. p. 340–1.
Cortes, Jorge, et al. “Superiority of Rasburicase Versus Allopurinol on Serum Uric Acid Control in Adult Patients with Hematological Malignancies at Risk of Developing Tumor Lysis Syndrome: Results of a Randomized Comparative Phase III Study.” BLOOD, vol. 112, no. 11, AMER SOC HEMATOLOGY, 2008, pp. 340–41.
Cortes J, Seiter K, Maziarz RT, Wetzler M, Craig M, Matous J, Luger S, Dey B, Schiller GJ, Pham D, Abboud CN, Krishnamurthy M, Brown A, Moore JO. Superiority of Rasburicase Versus Allopurinol on Serum Uric Acid Control in Adult Patients with Hematological Malignancies at Risk of Developing Tumor Lysis Syndrome: Results of a Randomized Comparative Phase III Study. BLOOD. AMER SOC HEMATOLOGY; 2008. p. 340–341.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2008
Volume
112
Issue
11
Start / End Page
340 / 341
Location
San Francisco, CA
Publisher
AMER SOC HEMATOLOGY
Conference Name
50th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology